AMSTERDAM, 30 NOVEMBER 2022

Certain statements and information contained in this presentation that are not statements or information of historical fact constitute forward-looking statements, notwithstanding that such statements are not specifically identified. These forward-looking statements may include statements regarding our (or our portfolio companies') plans, objectives, goals, strategies, future events, future revenue or performance, financing needs, plans or intentions relating to acquisitions, investments or capital expenditures, business trends or other information that is not historical information. These statements may include terminology such as "may", "will", "expect", "could", "should", "intend", "estimate", "anticipate", "believe", "remain", "on track", "design", "target", "objective", "goal", "forecast", "projection", "outlook", "prospects", "plan", "intend", or similar terminology. Forward-looking statements are related to future, not past, events and are not guarantees of future performance. These statements are based on current expectations, assumptions and projections about future events and, by their nature, address matters that are, to different degrees, uncertain and are subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future, and, as such, undue reliance should not be placed on them. Actual results may differ materially from those expressed in such statements as a result of a variety of factors, including among others:

- changes in general economic, financial and market conditions and other changes in business conditions;
- changes in commodity prices, the level of demand and financial performance of the major industries our portfolio companies serve; and
- changes in regulations and institutional framework (in each case, in Italy or abroad); and
- many other factors, most of which are outside of the control of EXOR.

These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements included in EXOR's Annual Report 2021, including those set forth under the heading "Risk Factors". These risks and uncertainties, as well as other risks of which we are not aware or which we currently do not believe to be material, may cause our actual future results to be materially different than those expressed in our forward-looking statements.

Investors and shareholders are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements speak only as of the date they are made. All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. EXOR undertakes no obligation to update or revise its outlook or forward-looking statements, whether as a result of new developments or otherwise. EXOR expressly disclaims and does not assume any liability in connection with any inaccuracies in any of these forward-looking statements or in connection with any use by any party of such forward-looking statements.

Names, organizations and company names referred to may be the trademarks of their respective owners.

This presentation does not represent investment advice neither a solicitation, nor a recommendation nor an invitation, nor an offer for the purchase or sale of financial products and/or of any kind of financial services as contemplated by the laws in any country or state.

- UPDATE
- COMPANIES
- VENTURES
- LINGOTTO
- FINANCIALS
- ESG
- WHAT'S NEXT?

IN 2022 WE CONTINUED TO EXECUTE ON OUR PRIORITIES

PEOPLE	 Implemented a new governance and organisational structure
COMPANIES	 Sold PartnerRe for \$9.3bn (~€8.6bn)¹ Supported the spin of Iveco Group from CNH Industrial Committed ~€1.0bn to Institut Mérieux and Lifenet
INVESTMENTS	 Continued our investments in Exor Ventures Created Lingotto, with ~\$2.4bn invested equally by Covéa and Exor
FINANCE	 Reduced gross debt by ~€0.6bn to ~€3.7bn Took advantage of high discount to NAV² to accelerate share buyback above €200m³ Transferred Exor's stock exchange listing to Euronext Amsterdam
ESG	 Offset our GHG emissions⁴ at holding level Launched pilot project to reduce the gender gap in STEM subjects

EXO

¹⁾ Equivalent amount in Euro based on exchange rate at closing on July 12th.

²⁾ Average discount to NAV in 2022 YTD ~44% compared to 5-year average (2017-2021) ~33%.

³⁾ Of which €100m bought back in the first half of 2022 (first tranche announced March 8th) and €114m bought back up to November 24th out of €250m (second tranche announced July 29th).


⁴⁾ Includes all Greenhouse Gas emissions. Based on emissions inventory produced in accordance with internationally acknowledged and recognised standards of the Greenhouse Gas Protocol initiative.

NEW APPOINTMENTS FURTHER STRENGTHEN OUR ORGANIZATION



THE SALE OF PARTNERRE RELEASED €9 BILLION OF CASH TO DEPLOY

in Euro billion



1) Including: i) Cash and equivalents position at 2021YE and listed securities ($\in 0.5bn$), ii) Net ordinary FCF in 2022 ($\in 0.4bn$) and net ordinary FCF est. in 2023-24 ($\in 1.1bn$) and iii) Tax settlement ($-\in 0.7bn$).

2) Equivalent amount in Euro of proceeds from sale of PartnerRe based on exchange rate at closing date on 12 July 2022.

3) Of which €0.2bn completed up to 24 November 2022.

4) Corresponding to €0.6bn maturing bond in December 2022, redeemed in October 2022 pursuant to the pre-maturity call option.

5) Out of the total ≤ 2.5 bn of cash allocated in 2022, ≤ 2.0 bn are funded and ≤ 0.5 bn unfunded. The unfunded portion corresponds to Institut Mérieux for a total of ≤ 0.5 bn based on a total commitment of ≤ 0.8 bn.

6) Exor invested in PartnerRe-managed reinsurance vehicles for a total of €0.7bn as part of the deal with Covéa, of which €0.3bn are expected to mature before 2024 and €0.4bn are expected to mature after 2024.

The amount to mature before 2024 is not included in the amount of 'cash allocated'.

7) Including investments in Exor Ventures (€0.1bn) and other investments.

Note: Numbers may not add due to rounding.

WE DIVIDE OUR PORTFOLIO INTO COMPANIES AND INVESTMENTS



Note: Gross Asset Value based on market prices at November 24th and private valuations at June 30th.

1) Including: Cash and equivalents ($\sim \in 5.4$ bn), Listed securities ($\sim \in 0.2$ bn), Reinsurance vehicles, financial investments and other assets including treasury shares ($\in 0.9$ bn).

IN 2021 WE SAID WE WOULD FOCUS ON THREE SECTORS

HEALTHCARE LUXURY **TECHNOLOGY** Is under-represented in our A non-cyclical sector with A highly resilient sector with structural tailwinds demographic tailwinds portfolio and has substantial growth potential Large sector with significant Can benefit from our long-term inefficiencies that may benefit capital and experience of family Our ownership of operating from our operational expertise companies make us attractive ownership partners to related technology companies Technology is changing the Technology-enabled healthcare connection with customers and solutions can be highly scalable We bring an understanding of fast increasing supply chain growth companies from our transparency Seeds investments

Open to new sectors and geographies where we can build great companies with great people

- UPDATE
- COMPANIES
- VENTURES
- LINGOTTO
- FINANCIALS
- ESG
- WHAT'S NEXT?

STARTING TO BUILD PRESENCE IN OUR FOCUS SECTORS

INCREASED OUR EXPOSURE TO LUXURY	EXPANDED OUR PRESENCE IN TECH		
Subouter OI <zox-></zox->	CASAVO		

2020

2022

Exor

 ✓ ~€1bn committed to Healthcare in 2022

ENTERED THE HEALTHCARE SPACE

INSTITUT MERIEUX

2022

Lifenet

2022

Healthcare

 Strengthened our network of practitioners to capture new opportunities

2020

2021

 ✓ ~€1bn invested in Tech (Companies and Ventures) over the last 5 years

INSTITUT MÉRIEUX IS A UNIQUE OPPORTUNITY...



WHAT MAKES INSTITUT MÉRIEUX UNIQUE? COMPANY **OWNERSHIP**¹ **INDUSTRY KEY FIGURES** €3.4bn Leading diagnostics player 2021 sales **59% 125 YEARS OF BUILDING GREAT** BIOMÉRIEUX #1 in Microbiology €11.7bn² #1 in Multiplex molecular COMPANIES market cap 100 MERIEUX 70% #2 in Food safety inspection accredited laboratories **ENTREPRENEURIAL CULTURE** and values that resonate with our own Growth & innovation capital >€1.3bn MERIEUX **60%** supporting 30+ companies AUM LEADING HEALTHCARE PLAYER 息 developing innovative public health solutions Niche competitor 3 CABI 100% in contract research and manufacturing manufacturing services facilities **GLOBAL PRESENCE** with 90+% of sales generated outside 160 employees with of France Immunotherapies pioneer **62%** transgene 70%+ in R&D in viral vectors engineering

2) Market cap as of November 24th.

...FOR EXOR TO BUILD A PARTNERSHIP THAT PAVES THE WAY FOR OUR AMBITIONS IN HEALTHCARE





€833m investment 10.0% ownership 2 of 11 Board Directors Closed on 29 July 2022



ACCELERATE INSTITUT MÉRIEUX'S DEVELOPMENT

- Shared ambition: to develop further and faster bioMérieux and the other companies of Institut Mérieux
- **Capital injection**: €833m to support its growth in its five verticals
- Strong partnership: as per our agreement, Exor is the privileged partner of Institut Mérieux and has liquidity options

EXPERTISE TO SUPPORT OUR OTHER PROJECTS IN HEALTHCARE

• Exchanging with Institut Mérieux and its companies brings Exor key insights on the trends shaping the future of the healthcare industry

OUR THREE LARGEST COMPANIES HAVE STRONG BALANCE SHEETS AND ARE WELL POSITIONED FOR THE FUTURE



PRESENTED THEIR NEW STRATEGIC PLANS	WHILE CONTINUING TO DELIVER	AND EXPLORING NEW OPPORTUNITIES
Pushing the Boundaries 2022 –2026	 Net revenues of €3.7bn YTD (+20% vs LY)¹ Net profit of €0.7bn YTD (+16% vs LY) Up to €0.7bn Industrial FCF in 2022E 2022 guidance revised upwards 	Ferrari PurosangueMilan Fashion Week
STELLINTIS Dare Forward 2030	 Net revenues of €130.1bn YTD (+21% vs LY)¹ Global BEV sales +41% (vs Q3 2021) Positive Industrial FCF in 2022E 2022 guidance confirmed 	SigafactoriesFree2move
EXAMPLE INDUSTRIAL Breaking New Ground 2022 – 2024	 Revenues² of \$16.6bn YTD (+19% vs LY)¹ Net profit of \$1.4bn YTD (+8% vs LY) > \$1.0bn Industrial FCF in 2022E 2022 guidance revised upwards 	Industry First Methane TractorRaven Technology at Work

YTD refers to the nine months ending on 30 September 2022; LY refers to the equivalent period for 2021.
 Refers to consolidated revenues that include financial services.

- UPDATE
- COMPANIES
- VENTURES
- LINGOTTO
- FINANCIALS
- ESG
- WHAT'S NEXT?

VENTURES IS INTEGRATED INTO EXOR PROVIDING INSIGHTS AND DEAL FLOW

Exor


EXOR VENTURES HAS BUILT A HIGH-QUALITY PORTFOLIO...

... SELECTIVELY GENERATING LARGER INVESTMENT OPPORTUNITIES



- Category leader in TransitTech
- 500+ deployments across 35 countries
- Resilient business model, strong unit economics
- Leading prop-tech platform in Europe
- Strong balance sheet and debt capital support
- Opportunity to consolidate the European market

WE HAVE INVESTED ~\$0.5 BILLION IN A BALANCED PORTFOLIO



We have invested in 71 companies, balanced across our core sectors, geography and stage

FOCUSED AND DISCIPLINED IN A VOLATILE ENVIRONMENT

Exor

HOW WE ARE ADAPTING	AREAS OF FOCUS		
 More selective, with the pace of investments slowing in the last two quarters 	Mobility, Fintech and Deeptech	Core focus over the last five yearsExor has strong institutional knowledge	
 Focus on higher conviction bets 	Healthcare	 Deep relationships with leading healthcare funds Thematic focus 	
 Re-underwriting our portfolio: management quality and company performance 	Climate-Tech	 Startups find Exor attractive 	
 Actively engaged with management teams 	Italy	 Growing tech ecosystem One of the most active early stage investors with Vento 	

- UPDATE
- COMPANIES
- VENTURES
- LINGOTTO
- FINANCIALS
- ESG
- WHAT'S NEXT?

REORGANIZATION OF EXOR'S INVESTMENT ACTIVITIES

Exor

FROM CAPTIVE INVESTMENT ACTIVITIES...

PartnerRe

~\$0.5bn Assets under Management (2017)

1 strategy (i.e. Public)

<5 investment professionals and back-office

Exor team

...TO AN ASSET MANAGEMENT COMPANY

Covéa and Exor

~\$2.4bn Assets under Management (2022)

2 strategies today (i.e. Public and Private)

~20 investment professionals and back-office

Lingotto team

We are re-organizing investment activities into Lingotto to continue to deliver attractive long-term returns to Covéa and Exor

WE HAVE PROVEN TRACK RECORD AND EXPERIENCE

~\$2.4bn¹ Assets Under Management today (~\$1.2bn Covéa, ~\$1.2bn Exor)

PUBLIC Matteo Scolari



- 20 years investing experience
- With Exor since 2016
- Senior Member Equity team Eton Park (responsible for >\$2bn AuM; gross average annualized returns of ~20%), management consulting at McKinsey, M&A at Goldman Sachs



- **PRIVATE** Nikhil Srinivasan
- 22 years investing experience
- With Exor since 2016²
- Chief Investment Officer PartnerRe, Group Chief Investment Officer Generali (responsible for >\$500bn AuM, outperformed return targets), Group Chief Investment Officer Allianz (>\$500bn AuM, outperformed targets)
- Theme-driven approach: innovation, consolidation, localisation, dislocation (macro / micro approach)
- Sector / capital structure agnostic, flexibility to invest in public assets
- Includes co-investments alongside specialised managers
- Bias to Europe and Asia,

NAV ~\$750m / ~ +11% ITD annualized performance³

Fundamental-driven approach

- Small number of high conviction stocks, long-term positions in public equity
- Investing on a long-only and long-and-short basis
- Global

NAV ~\$1,700m / ~ +16% ITD annualized performance³

- 2) Full time since Q3 2018.
- 3) Performance since April 2017 (Public) and since April 2021 (Private).

¹⁾ Based on Fund NAV figures at November 2022.



"Lingotto, one of the most impressive shows that the industry has ever offered"

Le Corbusier



- UPDATE
- COMPANIES
- VENTURES
- LINGOTTO
- FINANCIALS
- ESG
- WHAT'S NEXT?

DELIVERING ON OUR TARGETS IN THE SHORT AND LONG TERM...


		Our Targets	2022 YTD ¹	Last 5 years ²
OBJECTIVES	NAV/Share growth %	Outperform MSCI World Index	~(4)% vs. MSCI: ~(9)%√	~63% vs. MSCI: ~51% ✓
	TSR CAGR %	8%	~(5)%	~8%
EXOR KPIs	FCF ³ / Dividend paid	Above 1.0x	~5.0x ⁴ 🗸	~3.0x ⁵ 🗸
	Cash holding cost / GAV	Below 10bps	~6bps 🗸	~6bps 🗸
	Loan To Value ratio %	Below 20%	N/A ⁶	~8%

1) NAV/Share growth: from 1 January 2022 to 24 November 2022 ; FCF/Dividend paid, Cash holding cost: 2022 annualized data; Loan to Value ratio and GAV figures: at 24 November 2022.

- 2) NAV/share growth: from 24 November 2017 to 24 November 2022; FCF/Dividend paid, Cash holding cost: yearly average between 2018 and 2022E, Loan to Value ratio: yearly average between November 2018 November 2022
- 3) Free Cash Flow (FCF) defined as Dividend inflow Net general expenses Net financial expenses.
- 4) Based on Ordinary FCF. Including PartnerRe dividend received in March 2022 as part of the sale agreement, the ratio is equal to ~7.0x.
- 5) Based on Ordinary FCF. Including extraordinary dividends received between 2018 and 2022 the ratio is equal to ~6.0x.
- 6) Net cash position following sale of PartnerRe, therefore Loan To Value ratio not applicable.

Note: NAV figures at 24 November 2022 with updated market prices and private valuations at 30 June 2022.

...WHILE MANAGING OUR GROSS DEBT EFFICIENTLY...



All figures are expressed in millions and in the original currency of issuance

- Majority in Euro (~95%) and made up of bonds, with average maturity ~7 years and average fixed cost ~2.5%
- Reduced gross debt by ~€0.6bn in 2022
- Constant efforts to balance financing across different sources, maturity profiles and amounts
- Solid capital structure: BBB+ rating with stable outlook by S&P

4) Exor put in place a cross-currency swap on the bond issue.


¹⁾ Excluding accrued interest and amortized cost.

²⁾ Including only public bonds and private placements.

³⁾ Bond maturing in December 2022 redeemed in whole on October 2022 pursuant to the pre-maturity call option of the issuer.

...AND PRESERVING CASH AT BEST AVAILABLE YIELDS

CASH MANAGEMENT OBJECTIVES



MAIN CHARACTERISTICS

- Allocation to bank deposits (1-6 month duration) to leverage on short-term rates with no mark-to-market volatility. Exposure to ~7 counterparties with strong credit ratings
- Allocation to money market and short duration bond funds (<12 months) with high liquidity requirements managed by ~9 globally recognized asset managers
- Selective allocation to bond portfolio mandates focused on capital preservation, investing in investment grade securities and duration <24 months

- UPDATE
- COMPANIES
- VENTURES
- LINGOTTO
- FINANCIALS
- ESG
- WHAT'S NEXT?

WE ARE MAKING PROGRESS ON EXOR'S ESG COMMITMENTS...



OUR PASSIONS COMMITMENTS AT HOLDING LEVEL OUR PROGRESS **ENVIRONMENT** Measured Scope 1, 2 and 3 emissions \checkmark Achieve carbon neutrality by 2022 and **Emissions reduction** net zero emissions by 2025 Carbon neutral at holding level for FY2021 \checkmark Designed and launched an initiative to reduce the SOCIAL gender gap in STEM with Fondazione Agnelli Reduce the gender gap in STEM subjects **Education: decreasing** inequalities and Help high potential young entrepreneurs ✓ Working with young entrepreneurs through promoting innovation **Innovation 4 Change** GOVERNANCE ✓ 50 / 50 gender balance¹ Maintain 40/60 gender balance and consider diverse candidates for all new **Diversity and inclusion** Diverse candidates included on all Exor appointments appointment shortlists We have built networks of excellence and knowledge-sharing around these topics

...AND SUPPORTING OUR COMPANIES AS THEY PURSUE OUR SHARED ESG PASSIONS





- UPDATE
- COMPANIES
- VENTURES
- LINGOTTO
- FINANCIALS
- ESG
- WHAT'S NEXT?

WE WILL ALLOCATE CASH TO BOTH COMPANIES AND INVESTMENTS



WELL POSITIONED FOR THE CHALLENGES AND OPPORTUNITIES AHEAD

Strong companies with ambitious futures

Experienced and entrepreneurial leadership team

Ready to capture new opportunities

Solid track record of building great companies with great people

EXO

